Article

Differential Effects of 17 beta-Estradiol and of Synthetic Progestins on Aldosterone-Salt-Induced Kidney Disease

Department of Medicine, University of Würzburg, Germany.
Toxicologic Pathology (Impact Factor: 1.92). 10/2009; 37(7):969-82. DOI: 10.1177/0192623309350475
Source: PubMed

ABSTRACT Elevated mineralocorticoid levels and female sex hormones have been shown to confer opposing effects on renal injury, but their combined effects are still unknown.
Identify the function of estrogens and of different synthetic progestins on aldosterone salt-mediated renal disease.
The role of 17beta-estradiol, medroxyprogesterone acetate (MPA), and drospirenone during renal injury was studied in Wistar rats subjected to uni-nephrectomy plus aldosterone salt treatment.
Aldo-salt treatment of intact, ovariectomized, and estradiol-treated female rats resulted in remnant kidney hypertrophy without structural damage. Co-treatment with MPA, but not with drospirenone, increased kidney hypertrophy, fluid turnover, sodium retention, and potassium excretion. Medroxyprogesterone acetate also caused glomerular, vascular, tubular, and interstitial lesions that were accompanied by increased blood pressure and enhanced NADPH oxidase (p67phox) and sodium channel (alpha-ENaC) expression. Drospirenone, a progestin with anti-mineralocorticoid function, and spironolactone prevented kidney hypertrophy, hypertension, and sodium retention. Drospirenone and spironolactone also increased renal angiotensin II type 2 receptor expression and relieved aldosterone-induced suppression of serum angiotensin II levels.
The choice of specific synthetic progestins has profound implications on the development of kidney injury and renal gene expression under conditions of elevated aldosterone serum levels and salt intake.

0 Followers
 · 
154 Views
 · 
93 Downloads
  • Source
    • "The effects of different synthetic progestins are thus likely to be more complex and variable than those of endogenous progesterone (Oishi et al. 2004; Simoncini et al. 2004). We have recently shown that adding MPA to 17b-estradiol (E2) treatment worsens renal injury due to excess MR activation (Arias-Loza et al. 2009). Very few experimental studies have focused on the effect of unopposed (estradiol) versus combined (estradiol plus MPA) HRT, and no one has addressed the important question of whether the addition of MPA might aggravate chronic heart failure (HF) and left ventricular (LV) dysfunction following MI. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The role of estrogens during myocardial ischemia has been extensively studied. However, effects of a standard hormone replacement therapy including 17β-estradiol (E2) combined with medroxyprogesterone acetate (MPA) have not been assessed, and this combination could have contributed to the negative outcomes of the clinical studies on hormone replacement. We hypothesized that adding MPA to an E2 treatment would aggravate chronic heart failure after experimental myocardial infarction (MI). To address this issue, we evaluated clinical signs of heart failure as well as left ventricular (LV) dysfunction and remodeling in ovariectomized rats subjected to chronic MI receiving E2 or E2 plus MPA. After eight weeks MI E2 showed no effects. Adding MPA to E2 aggravated LV remodeling and dysfunction as judged by increased heart weight, elevated myocyte cross-sectional areas, increased elevated left ventricle end diastolic pressure, and decreased LV fractional shortening. Impaired LV function in rats receiving MPA plus E2 was associated with increased cardiac reactive oxygen species generation and myocardial expression levels of NADPH oxidase subunits. These results support the interpretation that adding MPA to an E2 treatment complicates cardiovascular injury damage post-MI and therefore contributes to explain the adverse outcome of prospective clinical studies.
    Toxicologic Pathology 06/2011; 39(5):867-78. DOI:10.1177/0192623311410441 · 1.92 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Different xTiO2–(60 − x)SiO2–40Na2O (5 ≤ x ≤ 20 wt.%) glasses are prepared in the form of plane parallel slabs. The optical constants of these optical glasses are determined over a wide spectral range, 0.2–3 μm, providing the complex dielectric constant to be calculated. The different dispersion parameters of the studied compositions are determined as well. Higher values for the refractive index and dispersion are recorded due to the high polarizability of Ti and the low preference of 4-coordination for titanium. The wavelength for zero material dispersion is evaluated. The second-order index of refraction and the third-order nonlinear optical susceptibility are computed from the measured linear refractive index data. These nonlinear properties of the present glass show one order of magnitude enhancement over some TiO2 silicate glasses. The measured mid-IR-spectra of the different glasses are carried out to investigate the structure of the present glasses. It has been found that, the addition of titanium (i.e., highly polarizable element) not only acts as glass modifier but also behaves as intermediate and Ti4+ exalts more the measured glass parameters.
    Materials Chemistry and Physics 04/2006; 96(2-3-96):201-210. DOI:10.1016/j.matchemphys.2005.07.022 · 2.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The mineralocorticoid receptor (MR) mediates aldosterone- and glucocorticoid-induced adipocyte differentiation. Drospirenone (DRSP) is a potent synthetic antimineralocorticoid with progestogenic and antiandrogenic properties, which is widely used for contraception and hormone replacement therapy. We investigated its potential role on adipocyte differentiation. The effects of DRSP were studied in murine preadipocyte cell lines and primary cultures of human preadipocytes. Differentiation markers and mechanisms underlying phenotypic variations in response to DRSP were explored. Early exposure to DRSP during differentiation led to a marked dose-dependent inhibition of adipose differentiation and triglyceride accumulation in 3T3-L1 and 3T3-F442A cells. DRSP also markedly inhibited adipose conversion of human primary preadipocytes derived from visceral (mesenteric and epicardial) and subcutaneous fat. This effect was MR-dependent and did not involve the glucocorticoid, androgen, or progesterone receptors. DRSP inhibited clonal expansion of preadipocytes and decreased expression of PPARγ, a key transcriptional mediator of adipogenesis, but had no effect on lipolysis, glucose uptake, and PPARγ binding to its ligands. DRSP exerts a potent antiadipogenic effect that is related to an alteration of the transcriptional control of adipogenesis via an antagonistic effect on the MR. Selective MR blockade therefore has promise as a novel therapeutic option for the control of excessive adipose tissue deposition and its related metabolic complications.
    Endocrinology 11/2010; 152(1):113-25. DOI:10.1210/en.2010-0674 · 4.64 Impact Factor
Show more